Diabetes (DM) Clinical Trial
Official title:
A Study to Investigate the Function, Safety and Tolerability of the FiberSense System in Diabetic Patients for a Period of Continuous Blood Glucose Monitoring up to 30 Days
| NCT number | NCT04152408 |
| Other study ID # | P-4.3-C-01 |
| Secondary ID | |
| Status | Completed |
| Phase | N/A |
| First received | |
| Last updated | |
| Start date | January 2017 |
| Est. completion date | April 2017 |
| Verified date | November 2019 |
| Source | EyeSense GmbH |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This is a single-centre, open label (unblinded) prospective study investigating the performance and safety of FiberSense system in diabetic patients (Typ I and II). In the period of up to 30 days the performance of the FiberSense system is evaluated against laboratory gold standard method during 6 in-clinic sessions.
| Status | Completed |
| Enrollment | 7 |
| Est. completion date | April 2017 |
| Est. primary completion date | April 2017 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Male or female age = 18 years old. - Type I or II diabetes mellitus. - Women who are not pregnant, lactating or planning a pregnancy during their participation in the clinical study. If of child bearing potential, the patient must agree to abstain from sexual intercourse or use reliable forms of contraception (e.g. condom or diaphragm with spermicide or oral contraceptives) to prevent pregnancy for the length of the clinical study. - Willingness, ability and commitment to comply with the testing procedure and follow-up outlined in this protocol including (but not limited to) frequency of clinic visits, use of pre-specified glucose monitoring device. - Willingness to abstain from swimming during their participation in the measurement phase. - Willingness to abstain from air travelling during their participation in the measurement phase. - Willingness to avoid strong magnetic and electrical fields as well as proximity to sensitive medical devices due to the possible electromagnetic interference during their participation in the measurement phase. - In the opinion of the investigator, absence of any physical limitations, addictive diseases, or underlying medical conditions (including mental health) that may preclude the patient from being a good study candidate. - Written informed consent to participate in the study provided by the patient. Exclusion Criteria: - Poorly controlled diabetes mellitus with HbA1C >10%. - Known microvascular (diabetic) complications (other than diabetic non-proliferative retinopathy), such as e.g. history of laser coagulation, proliferative diabetic retinopathy, known diabetic nephropathy (with glomerular filtration rate (eGFR) < 45 ml/min) or neuropathy requiring treatment. - History of significant hypoglycemia unawareness, or a history of severe hypoglycemia (requiring emergency medical intervention) within the last 6 months. - Currently pregnant, as demonstrated by a positive pregnancy test at screening and prior to enrollment. - Impaired hepatic function measured as aspartate aminotransferase (AST) = three times the upper reference limit. - Impaired renal function measured as creatinine > 1.2 times above the upper limit of normal. - Any active acute or chronic disease or condition that, in the opinion of the investigator, might interfere with the performance of this study. - Any active acute or chronic infectious disease that, in the opinion of the investigator, would pose an excessive risk to study staff. - Current use or recent exposure to any medication that in the opinion of the investigator could have an influence on the patient's ability to participate in this study or on the performance of the test device. - Extensive skin changes/diseases that preclude wearing the required number of devices on normal skin at the proposed application sites (e.g., extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, extensive tattoos, dermatitis herpetiformis). - Have a known allergy to medical-grade adhesives, or known hypersensitivity to any of the products used in the study. - Known current or recent alcohol or drug abuse - Blood donation of more than 500 ml within the last three months - Currently participating in another investigational study protocol where the testing or results may interfere with study compliance, diagnostic results, or data collection. - Has a MRI scan, CT scan, diathermy or flight scheduled during the proposed study participation. - An identified protected vulnerable patient (including but not limited to those in detention, or a prisoner). |
| Country | Name | City | State |
|---|---|---|---|
| Germany | Diabetes Institut Heidelberg | Heidelberg |
| Lead Sponsor | Collaborator |
|---|---|
| EyeSense GmbH |
Germany,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Performance of the FiberSense system as compared with laboratory gold standard reference (LGSR) | Point accuracy of the FiberSense system as determined by proportion of CGM readings within =15% of the LGSR reading for blood glucose levels >100 mg/dl, and within =15 mg/dl of the LGSR reading for blood glucose levels =100 mg/dl, for paired samples taken during the in-clinic sessions. | at 1, 3, 7, 14, 21 and 28 days | |
| Primary | Duration of use of the FiberSense system | Duration of use of the FiberSense device in average and by individual patients | 30 days | |
| Primary | Incidence of (Serious) Adverse Events | Adverse Events reporting and local tolerability as assessed by Draize's scale | 30 days | |
| Secondary | Mean and Median Relative Differences in FiberSense measured glucose from LGSR | at 1, 3, 7, 14, 21 and 28 days | ||
| Secondary | Mean and Median Absolute Relative Differences in FiberSense measured glucose from reference laboratory standard | at 1, 3, 7, 14, 21 and 28 days | ||
| Secondary | Hypoglycemia (<75 mg/dl (14)) and hyperglycemia (>180 mg/dl (14)) detection rates | at 1, 3, 7, 14, 21 and 28 days | ||
| Secondary | Hypoglycemia (<75 mg/dl) and hyperglycemia (>180 mg/dl,) missed detection rates | at 1, 3, 7, 14, 21 and 28 days | ||
| Secondary | Accuracy of glucose rate of change of FiberSense sensor compared to glucose rate of change of reference laboratory standard | at 1, 3, 7, 14, 21 and 28 days | ||
| Secondary | Lag time between FiberSense readings and reference laboratory standard results during induced glucose excursions | at 1, 3, 7, 14, 21 and 28 days | ||
| Secondary | Agreement and accuracy relative to SMBG readings (same model to be used by all patients) | Performance of SMBG evaluated as percentage of system readings within 15%, 20%, 30% and 40% of LGSR values and by means of MARD and MedARD(%) | weekly - Days 7, 14, 21, 28 | |
| Secondary | Stability of the FiberSense fluorescence measurements | The stability of sensor performance over the 30-day time period evaluated as percentage of FiberSense system readings within 15%, 20%, 30% and 40% of LGSR values and by means of MARD and MedARD(%) | weekly - Days 7, 14, 21, 28 | |
| Secondary | User satisfaction assessed by the Likert scale | Subjective impression of the patients on the scale of 1 (strongly agree) to 5 (strongly disagree) | 30 days |